Lexaria Bioscience Secures $2 Million in Registered Direct Offering
Lexaria Bioscience has entered into a definitive agreement to raise $2 million through a registered direct offering of common stock, providing capital for working capital and general corporate purposes.
Lexaria Bioscience Corp., a drug delivery platforms innovator, has announced a registered direct offering of 2 million shares of common stock at $1.00 per share, expected to generate gross proceeds of $2 million. The transaction, facilitated by H.C. Wainwright & Co. as the exclusive placement agent, is anticipated to close on or around April 28, 2025.
The offering will be conducted under an existing shelf registration statement previously declared effective by the Securities and Exchange Commission. The company intends to use the net proceeds for working capital and general corporate purposes, signaling a strategic approach to maintaining financial flexibility.
This financial maneuver comes as Lexaria continues to develop its DehydraTECH drug delivery platform, which has demonstrated potential improvements in bio-absorption and drug delivery across various applications. The capital raise suggests the company is positioning itself to advance its research and development initiatives.
The registered direct offering represents a calculated method for Lexaria to secure necessary funding while maintaining transparency through proper SEC registration procedures. By utilizing a single institutional investor, the company can efficiently raise capital with minimal market disruption.